About This Dosing Guide

The Mayzent (siponimod) Dose Calculator is a clinical tool designed to help healthcare professionals determine the correct maintenance dose and titration schedule based on a patient’s CYP2C9 genotype. This guide provides supporting information on the tool’s outputs, clinical context for dosing decisions, and answers to frequently asked questions about Mayzent administration.

Outputs Explained

Based on the selected genotype, the calculator provides a comprehensive dosing recommendation, including:

• Dosing Status: Clearly indicates if the patient is eligible for a ‘Standard Dose,’ a ‘Reduced Dose,’ or if Mayzent is ‘Contraindicated.’
• Maintenance Dose: Specifies the recommended once-daily maintenance dose (2 mg or 1 mg) after the initial titration period.
• Titration Schedule: Provides a day-by-day upward titration schedule to mitigate potential cardiac effects (e.g., bradycardia) upon treatment initiation.
• Clinical Note: Offers an important reminder from the prescribing information, such as the contraindication for CYP2C9*3/*3 patients or the need for first-dose monitoring.

How to Use the Calculator

The tool is designed for simplicity and immediate feedback. To use the calculator, a healthcare professional must first determine the patient’s CYP2C9 genotype via a validated test.

1. Locate the “Patient CYP2C9 Genotype” dropdown menu.
2. Select the patient’s genotype (e.g., *1/*1, *1/*3, etc.) from the list.
3. The recommended dosing regimen, including the titration schedule and maintenance dose, will be displayed instantly in the output section.
4. The “Reset” button clears the selection and the results.

Dosing Overview

Siponimod is primarily metabolized by the CYP2C9 enzyme. A patient’s genetic variation in this enzyme dictates their ability to process the drug, requiring dose adjustments to ensure safety and efficacy.

• Normal Metabolizers (e.g., *1/*1, *1/*2, *2/*2): These patients can receive the standard 2 mg maintenance dose following a 6-day titration.
• Intermediate Metabolizers (e.g., *1/*3, *2/*3): These patients require a reduced maintenance dose of 1 mg to avoid drug accumulation and potential adverse effects. The titration schedule is also modified, lasting 5 days.
• Poor Metabolizers (*3/*3): Drug exposure is significantly increased in these patients, leading to an unacceptable safety risk. Therefore, Mayzent is contraindicated in patients with a CYP2C9*3/*3 genotype.

Switching to Mayzent

When switching a patient from another disease-modifying therapy (DMT) to Mayzent, a washout period may be necessary to minimize the risk of additive immunosuppressive effects. The duration of the washout depends on the previous therapy’s half-life and mechanism of action. Consult the Mayzent prescribing information for specific guidance on switching from different DMTs.

Missed Dose Protocol

Adherence is critical, especially during the initial titration phase. The protocol for a missed dose varies based on when it occurs:

• During Titration (First 6 days for 2 mg, first 5 days for 1 mg): If one dose is missed, treatment must be re-initiated with Day 1 of the titration schedule. This requires a new starter pack and first-dose monitoring.
• During Maintenance (After titration is complete): If a single maintenance dose is missed, the patient should take the next dose at the scheduled time. They should not double the dose. If 4 or more consecutive daily doses are missed, treatment must be re-initiated with Day 1 of the titration schedule.

Safety Alerts

The use of Mayzent requires careful patient selection and monitoring due to potential risks.

• Bradyarrhythmia and Atrioventricular Conduction Delays: Mayzent can cause a transient decrease in heart rate. First-dose monitoring, including an EKG, is required for patients with certain pre-existing cardiac conditions.
• Infections: Mayzent causes a dose-dependent reduction in peripheral lymphocyte count, which may increase the risk of infections. A complete blood count (CBC) should be obtained before initiation.
• Macular Edema: An ophthalmologic evaluation is recommended before starting treatment and at any time a patient reports visual disturbances.
• Liver Injury: Liver function tests should be evaluated prior to initiation.

Frequently Asked Questions

Why is CYP2C9 genotyping required before starting Mayzent?

CYP2C9 is the primary enzyme responsible for metabolizing siponimod. Genetic variants can significantly slow this metabolism, leading to higher drug levels and an increased risk of side effects. Genotyping is mandatory to identify patients who need a lower dose or who cannot take the drug at all (*3/*3 genotype).

What happens if a patient’s genotype is CYP2C9*3/*3?

Use of Mayzent is contraindicated. These patients are “poor metabolizers,” and taking siponimod would lead to dangerously high drug concentrations, posing a significant safety risk.

What is the purpose of the dose titration for siponimod?

The gradual dose increase (titration) over the first 5-6 days is a safety measure to mitigate the acute cardiac effects of S1P receptor modulators, primarily the risk of bradycardia (slowing of the heart rate) that can occur upon treatment initiation.

What monitoring is required on Day 1 of Mayzent treatment?

All patients require assessment of their heart rate and blood pressure. For patients with certain pre-existing cardiac conditions (e.g., sinus bradycardia, history of MI or heart failure), 6-hour monitoring with EKG is required after the first dose.

Can a patient with a *1/*3 genotype take the 2 mg maintenance dose?

No. Patients with a CYP2C9*1/*3 or *2/*3 genotype are intermediate metabolizers and must receive the reduced maintenance dose of 1 mg daily to prevent drug accumulation and potential toxicity.

What should a patient do if they miss one dose of Mayzent during the titration period?

They must stop and re-start the entire titration process from Day 1, using a new titration starter pack. First-dose monitoring procedures must be followed again.

What should a patient do if they miss one maintenance dose of Mayzent?

They should take their next scheduled dose as planned the following day. They should not take an extra dose to make up for the missed one.

How does hepatic impairment affect Mayzent dosing?

Dosing adjustments are required for patients with moderate hepatic impairment (Child-Pugh B), and the recommended maintenance dose is 1 mg. Mayzent is not recommended in patients with severe hepatic impairment (Child-Pugh C).

Are there any significant drug interactions with Mayzent?

Yes. Concomitant use with strong CYP2C9 inhibitors (e.g., fluconazole) or moderate dual CYP2C9/CYP3A4 inhibitors can significantly increase siponimod exposure and is not recommended. Consult the full prescribing information for a complete list.

Does this calculator apply to pediatric patients?

The calculator reflects dosing for adults with relapsing forms of multiple sclerosis. Mayzent is also approved for pediatric patients 10 years of age and older, but dosing is body-weight based and differs from the adult regimen. This calculator should not be used for pediatric dosing.

References